BioCentury | Apr 4, 2005
Finance

2Q milestones

...III CV Therapeutics (CVTX) Ranexa Angina Ph III data Encysive (ENCY) Thelin Hypertension Submit NDA Enhance Biotech/DMI...
BioCentury | Jan 10, 2005
Finance

Upcoming milestones

...III data 1H05 Encysive Thelin (TBC11251) Hypertension Prelim Ph III data; submit NDA 2/05; 4/05 Enhance Biotech/DMI...
BioCentury | Jan 3, 2005
Company News

Ardent, Enhance Biotech deal

...for male sexual dysfunction and dermatology indications. Ardent Pharmaceuticals Inc. , Research Triangle Park, N.C. Enhance Biotech Inc....
BioCentury | Nov 8, 2004
Company News

Ardent, J&J deal

...also received exclusive options to license additional analgesic compounds from Ardent. Ardent is merging with Enhance Biotech Inc....
BioCentury | Oct 11, 2004
Clinical News

LI 301: Phase III started

...Phase III trial that will involve about 80 couples. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
BioCentury | Sep 20, 2004
Clinical News

LI 401: Phase IIa start

...U.K. Phase IIa trial in about 20 healthy volunteers. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
BioCentury | Aug 16, 2004
Company News

Ardent, Enhance Biotech deal

...for male sexual dysfunction and dermatology indications. Ardent Pharmaceuticals Inc. , Research Triangle Park, N.C. Enhance Biotech Inc....
BioCentury | May 17, 2004
Company News

Enhance Biotech board of directors update

Enhance Biotech Inc. (EBOI), New York, N.Y. Business: Genitourinary, Dermatology Appointed: David Scales, director of product R&D at Antisoma Research Ltd. WIR Staff...
BioCentury | Mar 29, 2004
Company News

Enhance Biotech, Covance deal

...and psoriasis. LI 313, now in Phase I, is a topically applied T cell mediator. Enhance Biotech Inc....
BioCentury | Mar 8, 2004
Clinical News

LI 301: Phase IIa

...to placebo. EBOI is co-developing LI 301 with DMI. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
Items per page:
1 - 10 of 11
BioCentury | Apr 4, 2005
Finance

2Q milestones

...III CV Therapeutics (CVTX) Ranexa Angina Ph III data Encysive (ENCY) Thelin Hypertension Submit NDA Enhance Biotech/DMI...
BioCentury | Jan 10, 2005
Finance

Upcoming milestones

...III data 1H05 Encysive Thelin (TBC11251) Hypertension Prelim Ph III data; submit NDA 2/05; 4/05 Enhance Biotech/DMI...
BioCentury | Jan 3, 2005
Company News

Ardent, Enhance Biotech deal

...for male sexual dysfunction and dermatology indications. Ardent Pharmaceuticals Inc. , Research Triangle Park, N.C. Enhance Biotech Inc....
BioCentury | Nov 8, 2004
Company News

Ardent, J&J deal

...also received exclusive options to license additional analgesic compounds from Ardent. Ardent is merging with Enhance Biotech Inc....
BioCentury | Oct 11, 2004
Clinical News

LI 301: Phase III started

...Phase III trial that will involve about 80 couples. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
BioCentury | Sep 20, 2004
Clinical News

LI 401: Phase IIa start

...U.K. Phase IIa trial in about 20 healthy volunteers. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
BioCentury | Aug 16, 2004
Company News

Ardent, Enhance Biotech deal

...for male sexual dysfunction and dermatology indications. Ardent Pharmaceuticals Inc. , Research Triangle Park, N.C. Enhance Biotech Inc....
BioCentury | May 17, 2004
Company News

Enhance Biotech board of directors update

Enhance Biotech Inc. (EBOI), New York, N.Y. Business: Genitourinary, Dermatology Appointed: David Scales, director of product R&D at Antisoma Research Ltd. WIR Staff...
BioCentury | Mar 29, 2004
Company News

Enhance Biotech, Covance deal

...and psoriasis. LI 313, now in Phase I, is a topically applied T cell mediator. Enhance Biotech Inc....
BioCentury | Mar 8, 2004
Clinical News

LI 301: Phase IIa

...to placebo. EBOI is co-developing LI 301 with DMI. DMI BioSciences Inc. , Englewood, Colo. Enhance Biotech Inc....
Items per page:
1 - 10 of 11